Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-CART2219.1 in R/R B-cell Malignancies
NCT07108868Phase 1Recruiting
- Sponsor
- University Hospital Tübingen
- Start
- Jun 2025
- Primary completion
- Mar 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MB-CART2219.1 in B cell lymphoma, chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL), sponsored by University Hospital Tübingen. Primary endpoint: Safety and feasibility Phase I (CTCAE) at 6 months. Started Jun 2025; status: recruiting.
02
Drugs
MB-CART2219.1
03
Conditions
B cell lymphomachronic lymphocytic leukemia (CLL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07108868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07108868.